Pfizer pays $330m upfront for China's Starna in $2.6bn CAR-T deal
Pfizer has licensed three preclinical in-vivo CAR-T programmes from China's Starna Therapeutics for $330m upfront and up to $2.3bn in milestones, plus royalties, in a deal announced on 18 November.
What happened
Pfizer signed an exclusive licensing agreement with Starna Therapeutics, a China-based biotech working on RNA delivery for in-vivo CAR-T therapies. The deal, announced on 18 November, covers three early-stage programmes in autoimmune disease. Pfizer takes development, manufacturing and commercial rights outside Greater China, and will make initial clinical trial supply at its US facilities.
The numbers
| Item | Value |
|---|---|
| Upfront | $330m |
| Milestones | Up to $2.3bn |
| Total | About $2.6bn, plus royalties |
| Programmes | Three, all preclinical |
Why it matters
Out-licensing is now the main route for Chinese biotechs to capture international value without a US listing. The upfront is the number that matters to founders deciding between a China-only launch and a partner-led global one: $330m is real money before any trial reads out, and it validates RNA delivery for in-vivo CAR-T.
The counter-argument is that three preclinical programmes carry high attrition, and most of the $2.6bn is contingent. Pfizer's $10.5bn Innovent deal in May and its earlier 3SBio pact show a pattern rather than a one-off, which is the stronger signal for China biotech valuations.
What to watch
- IND clearance and first-in-human dosing.
- Milestone timing and any expansion of the Starna collaboration.
- Whether other global pharma groups bid for similar Chinese assets.
Original source: BioSpace · 18 Nov 2026
